AI Oncology Imaging Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 0.6 billion
Estimated Base Value
2035 Forecast
US$ 3.4 billion
Projected Market Value
CAGR 2026–2035
18.9%
Compound Annual Growth
Largest Segment
AI-powered Computer-Aided Detection (CADe)
Fastest Growing Segment
AI-Powered Prognosis and Prediction
Leading Region
Asia Pacific
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
38.5% market share
Key Players
Paige.AI
Emerging Players
Tempus, Vara
Market Definition & Overview
The AI Oncology Imaging Market encompasses the advanced integration of artificial intelligence technologies within medical imaging devices and software solutions specifically designed for cancer care. This market focuses on AI applications that enhance the acquisition, processing, interpretation, and analysis of diagnostic images (such as CT, MRI, PET, ultrasound, and mammography) to improve the detection, diagnosis, staging, prognosis, and treatment planning for various cancers. It includes AI-powered tools that aid radiologists and oncologists in identifying subtle abnormalities, segmenting tumors, predicting treatment response, and personalizing patient management, thereby improving diagnostic accuracy and efficiency in oncology workflows.
Scope
- Global coverage across key regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
- Segmentation by imaging modality: CT, MRI, PET, X-ray, Ultrasound, Mammography.
- Segmentation by application: Cancer Detection, Diagnosis, Staging, Treatment Planning, Monitoring.
- Analysis period from current year up to a specified forecast horizon (e.g., 2023-2030).
Inclusions
- AI software platforms for cancer detection in medical images.
- AI algorithms for tumor segmentation and characterization across modalities.
- AI-powered Computer-Aided Detection (CAD) and Diagnosis (CADx) systems for oncology.
- AI solutions integrated with imaging devices for automated analysis.
- Machine learning tools for predicting cancer treatment response from images.
- Deep learning applications for radiation oncology planning based on imaging.
Exclusions
- General AI solutions in healthcare not specifically for oncology.
- Non-imaging AI applications in oncology, such as genomics or drug discovery AI.
- Traditional medical imaging equipment without integrated AI capabilities.
- AI for non-cancerous conditions or general diagnostic radiology.
- Standalone Picture Archiving and Communication Systems (PACS) without AI functionalities.
Market Size Forecast
Executive Summary
• The AI Oncology Imaging market is valued at $0.6 Bn in 2025 and is forecast to reach $3.4 Bn by 2035, reflecting a robust CAGR of 18.9% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-powered Computer-Aided Detection (CADe) leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 33.0%.
• United States remains the single largest country-level market at 38.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Consolidation intensifies as major medical imaging players acquire specialized AI developers, integrating advanced algorithms and securing data access, fundamentally reshaping the competitive landscape and driving ecosystem verticalization across oncology pathways.
• Clinical validation and proven ROI in improving diagnostic accuracy and physician workflow efficiency remain critical catalysts, accelerating widespread adoption and driving demand for integrated AI solutions across diverse oncology care settings globally.
• Regulatory harmonization and the increasing sophistication of multi-modal AI models, including federated learning capabilities, are pivotal for overcoming data silos and enabling comprehensive, patient-centric cancer management solutions across jurisdictions.
• Developed markets prioritize AI for precision treatment planning and early detection, while emerging economies focus on basic diagnostic augmentation and accessibility, creating distinct regional strategic imperatives for market penetration and product development.
• Significant venture capital investment targets novel AI platforms for prognosis and recurrence prediction, yet successful hospital integration necessitates robust IT infrastructure and comprehensive clinician training to realize full operational benefits.
• The market's future hinges on seamless integration of AI-powered imaging with genomics and pathology, enabling true precision oncology by personalizing treatment trajectories and optimizing patient outcomes from initial diagnosis.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The AI Oncology Imaging Market is valued at $0.6 billion in the base year, indicating its foundational presence in medical diagnostics.
Future Market Projection
This market is projected for substantial growth, reaching $3.4 billion by the forecast year, reflecting strong anticipated adoption.
Exceptional Growth Rate
An impressive Compound Annual Growth Rate (CAGR) of 18.9% is expected, highlighting the rapid expansion and increasing importance of AI in oncology imaging.
Significant Market Expansion
The market demonstrates significant expansion potential, growing from $0.6 billion to $3.4 billion, underscoring the transformative impact of AI in cancer care.
AI Integration Drives Growth
Increasing integration of artificial intelligence solutions into oncology imaging workflows is a primary driver, revolutionizing diagnostic capabilities across healthcare settings.
Precision Diagnostics Trend
A notable trend fueling market growth is the escalating demand for enhanced accuracy, efficiency, and personalized treatment planning in cancer detection and management through AI.
Market Dynamics
Market Trends
- Increasing integration of AI tools into routine radiology workflows.
- Growing demand for explainable AI to build clinician trust and adoption.
- Emergence of multi-modal AI combining various imaging and clinical data.
- Stronger focus on AI for personalized cancer diagnosis and treatment planning.
Growth Drivers
- Rising global cancer incidence drives demand for early, precise diagnosis.
- Radiologist shortages prompt AI adoption for improved efficiency and accuracy.
- Continuous advancements in AI algorithms and computing power fuel innovation.
- Increasing investments and government funding for digital health technologies.
Restraints
- Stringent regulatory approval processes delay market entry and product adoption.
- Limited availability of diverse, high-quality, annotated oncology imaging datasets.
- Challenges in seamlessly integrating AI solutions into existing clinical workflows.
- Hesitancy among medical professionals to fully trust AI-driven diagnostic tools.
Opportunities
- Significant untapped potential in expanding AI solutions to emerging economies.
- Developing specialized AI for early detection of rare or aggressive cancers.
- AI for predictive analytics in treatment response and recurrence monitoring.
- Seamless integration of AI with existing hospital information systems (EHR/PACS).
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Powered Computer-Aided DetectionAI-Powered Computer-Aided DiagnosisAI-Powered Prognosis and PredictionAI-Powered Treatment Planning & Response AssessmentAI-Powered Workflow & Image ManagementAI-Powered Image Reconstruction & EnhancementAI-Driven Drug Discovery & Biomarker IdentificationAI-Powered Medical Device Integration Software |
| By Technology | Deep LearningMachine LearningNatural Language ProcessingComputer VisionPredictive AnalyticsReinforcement LearningGenerative AI |
| By Application | Breast CancerLung CancerProstate CancerColorectal CancerBrain CancerLiver CancerHead & Neck CancerOther Cancers |
| By End-User | HospitalsDiagnostic Imaging CentersCancer Research CentersPharmaceutical & Biotechnology CompaniesAcademic & Research InstitutesSpecialty ClinicsContract Research Organizations |
| By Deployment | On-PremiseCloud-BasedHybridEdge Computing |
| By Imaging Modality | Computed TomographyMagnetic Resonance ImagingPositron Emission TomographyUltrasoundX-RayMammographyDigital PathologySingle-Photon Emission Computed Tomography |
Regional Analysis
- North America dominates the AI Oncology Imaging market due to its advanced healthcare infrastructure, significant R&D investments, and rapid adoption of innovative technologies. High prevalence of cancer and a strong presence of key industry players further solidify its leading position in medical device integration.
- Asia-Pacific is the fastest-growing region for AI Oncology Imaging, driven by rapidly improving healthcare infrastructure and substantial government investments in digital health. Rising cancer prevalence and growing demand for early, precise diagnostics in economies like China and India propel this accelerated market expansion.
- Europe is witnessing a significant trend towards stringent regulatory frameworks for AI in oncology imaging, notably influenced by the EU AI Act. This emphasis on data privacy, ethical AI, and standardized validation processes is shaping product innovation and market entry across European Union countries.
Asia Pacific
16.5% CAGR
$0.2 Bn
33% share
- Driven by massive patient populations, increasing healthcare expenditure, and robust government initiatives, particularly in China and India, this region is witnessing rapid adoption of AI oncology imaging solutions, fostering local innovation and strategic partnerships.
North America
15.0% CAGR
$0.2 Bn
30% share
- A mature yet highly innovative market, North America leads in R&D and early adoption of cutting-edge AI technologies for oncology imaging, supported by significant private investment, established healthcare infrastructure, and favorable regulatory pathways.
Europe
14.0% CAGR
$0.1 Bn
25% share
- Characterized by strong public healthcare systems and a growing focus on digital health, Europe demonstrates steady adoption of AI oncology imaging, with ongoing efforts to standardize regulations and foster cross-border collaboration in research and clinical implementation.
Latin America
13.0% CAGR
$0.0 Bn
6% share
- This region represents a developing market for AI oncology imaging, marked by increasing healthcare investments and a growing awareness of AI's benefits, though adoption rates vary significantly across countries due to economic disparities and infrastructure challenges.
Middle East & Africa
12.0% CAGR
$0.0 Bn
4% share
- The market here is highly diverse, with significant investments in advanced medical technologies in GCC countries driving rapid adoption, while other sub-regions face hurdles like limited infrastructure and funding, leading to a fragmented but growing landscape.
Emerging Areas
9.0% CAGR
$0.0 Bn
2% share
- Comprising nascent and smaller geographies, these areas show initial interest in AI oncology imaging, albeit with extremely low penetration due to underdeveloped healthcare infrastructure, economic constraints, and limited access to specialized technology and expertise.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.2 Bn | 19.8% | Leading the market due to significant R&D investment, high adoption of advanced medical technologies, and a large patient base. Strong regulatory support and a robust ecosystem for AI innovation further drive its growth in oncology imaging. |
| 2 | Brazil | $0.0 Bn | 17.2% | The largest healthcare market in South America, demonstrating growing adoption of digital health solutions and increasing investment in medical technology. Its large population and rising cancer incidence drive the demand for advanced AI oncology imaging. |
| 3 | Germany | $0.0 Bn | 17.5% | A frontrunner in medical technology and research, with a robust healthcare system and significant investments in precision medicine and digital health. High-quality clinical data and strong industry-academia collaborations fuel its AI oncology imaging market. |
| 4 | China | $0.1 Bn | 23.5% | Dominates the APAC market due to a vast patient population, aggressive government support for AI and healthcare innovation, and rapid digital infrastructure expansion. Its focus on early cancer screening and diagnosis is a major driver for AI oncology imaging. |
| 5 | Saudi Arabia | $0.0 Bn | 18.5% | Undergoing significant healthcare transformation as part of Vision 2030, with substantial government investment in advanced medical infrastructure and digital health. High cancer incidence rates and a focus on early detection drive the adoption of AI oncology imaging. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Paige.AI | 5.7% | Focus on developing AI-powered diagnostic solutions for pathology to aid cancer diagnosis and prognosis. | Spun out of Memorial Sloan Kettering Cancer Center, giving it strong clinical foundations. | Received FDA clearance for Paige Breast Detect, its AI-powered breast cancer detection software. | Paige Prostate DetectPaige Breast DetectPaige Gastric Detect+1 |
| 2 | Lunit | 5.4% | Develop AI solutions for precision diagnostics and therapeutics, covering both imaging and pathology. | One of the few companies with a strong presence in both radiology and pathology AI. | Expanded partnerships with global medical device companies for integration of its AI solutions. | Lunit INSIGHT MMGLunit INSIGHT CXRLunit SCOPE IO+1 |
| 3 | Aidoc | 5.1% | Provide AI solutions that triage and flag critical findings in medical images, accelerating radiologist workflow. | Focuses on acute care AI solutions that significantly reduce turnaround times for critical cases. | Expanded its AI platform to cover additional medical conditions and imaging modalities. | Aidoc aiWorklistAidoc BrainAidoc Pulmonary Embolism+1 |
| 4 | PathAI | 4.9% | Leverage AI and machine learning to improve the accuracy and efficiency of pathology diagnosis and accelerate drug development. | Collaborates extensively with pharmaceutical companies for companion diagnostics and drug development. | Formed new partnerships with biopharmaceutical companies to advance precision medicine using AI pathology. | PathAI Dx platformAISightClinician Insights+1 |
| 5 | Ibex Medical Analytics | 4.6% | Develop AI-powered cancer diagnostics in pathology to assist pathologists in improving accuracy and efficiency. | Pioneered AI solutions for primary diagnosis in pathology, receiving regulatory clearances for such use. | Expanded its Galen AI platform to new tissue types and gained further international regulatory approvals. | Galen ProstateGalen BreastGalen Gastric+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Paige.AI, Lunit, Aidoc, PathAI, Ibex Medical Analytics, Qure.ai, Volpara Health Technologies, Nanox Imaging, Elekta, ScreenPoint Medical, Vuno, Aidence, Proscia, Accuray, Therapixel, Riverain Technologies, Beijing Infervision Technology, DeepMotion Medical, Imagen Technologies, Viz.ai
The global AI Oncology Imaging market features a competitive landscape led by Paige.AI, Lunit, Aidoc, PathAI, Ibex Medical Analytics, and Qure.ai, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Paige.AI
Lunit
Aidoc
PathAI
Ibex Medical Analytics
Qure.ai
Volpara Health Technologies
Nanox Imaging
Elekta
ScreenPoint Medical
Vuno
Aidence
Proscia
Accuray
Therapixel
Riverain Technologies
Beijing Infervision Technology
DeepMotion Medical
Imagen Technologies
Viz.ai
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
AI-Powered Prostate Cancer Detection Tool Gains FDA Clearance
A prominent AI medical imaging company announced FDA clearance for its novel AI software, designed to enhance the accuracy and efficiency of prostate cancer detection on MRI scans, promising to reduce radiologist workload and improve diagnostic consistency.
Major Hospital Network Adopts AI for Lung Cancer Screening
A leading AI oncology imaging firm partnered with a national hospital network to integrate its AI-powered lung nodule detection software across multiple imaging centers. This collaboration aims to significantly improve early detection rates for lung cancer patients nationwide.
AI Oncology Imaging Innovator Secures $50M Series C Funding
An emerging leader in AI-driven personalized cancer treatment planning announced a successful $50 million Series C funding round. The substantial capital will fuel further research and development, alongside commercial expansion of its predictive imaging analytics platform.
Health Tech Giant Acquires Leading AI Radiomics Firm
A major health technology conglomerate acquired a prominent AI company specializing in radiomics for cancer prognostication. This strategic move aims to integrate advanced predictive analytics into its comprehensive oncology solutions portfolio, enhancing treatment stratification capabilities.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $0.6 Bn |
| Market Size (Forecast) | $3.4 Bn |
| CAGR | 18.9% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 42 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included